Vision Financial Markets LLC Buys Shares of 3,000 ADMA Biologics, Inc. (NASDAQ:ADMA)

Vision Financial Markets LLC bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 3,000 shares of the biotechnology company’s stock, valued at approximately $51,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Arizona State Retirement System increased its holdings in ADMA Biologics by 6.6% during the 4th quarter. Arizona State Retirement System now owns 67,581 shares of the biotechnology company’s stock valued at $1,159,000 after acquiring an additional 4,170 shares in the last quarter. Victory Capital Management Inc. increased its holdings in ADMA Biologics by 52.8% during the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company’s stock valued at $1,886,000 after acquiring an additional 38,002 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in ADMA Biologics by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company’s stock valued at $41,851,000 after acquiring an additional 38,761 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in ADMA Biologics during the 4th quarter valued at about $141,000. Finally, Jones Financial Companies Lllp increased its holdings in ADMA Biologics by 303.4% during the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 4,312 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $17.68 on Thursday. The company has a 50-day simple moving average of $16.69 and a 200-day simple moving average of $17.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 12 month low of $5.71 and a 12 month high of $23.64. The company has a market cap of $4.18 billion, a PE ratio of 63.14 and a beta of 0.75.

Analyst Ratings Changes

ADMA has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.